NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced ...
This is particularly exciting as these findings credential the opportunity to leverage an ADC approach for a broad population of patients. In preclinical studies with human tumor models, three total ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results